Flex Pharma Inc., of Boston, said its stockholders approved all proposals relating to its planned merger with Houston-based Salarius Pharmaceuticals LLC at its special meeting. The merger is expected to be completed within the next two weeks.

Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it is now compliant with the minimum bid price requirement for continued listing on Nasdaq and is no longer subject to delisting at this time. To achieve compliance, the company implemented a 1-for-9 reverse stock split last month.

Schrodinger Inc., of New York, said it received a preclinical milestone payment from Sanofi SA, of Paris, in a drug discovery program advancing as part of a multiyear, multitarget collaboration.

Volitionrx Ltd., of Austin, Texas, was awarded a $1.4 million grant from the Walloon Region in Belgium to support a collaboration with Giga at the University of Liege, Belgium. The project will study the use of telomere maintenance as a cancer diagnostic using Volitionrx's Nucleosomics platform.

Cytomx Therapeutics Inc., of South San Francisco, will receive a $10 million payment from Abbvie Inc., of North Chicago, for the selection of a second target under their 2016 collaboration to discover and develop Probody drug conjugates.

Batavia Biosciences BV, of Leiden, the Netherlands, received a follow-up grant of $2.2 million from the global nonprofit Path, to develop and manufacture novel oral poliovirus vaccines. 

Novelion Therapeutics Inc., of Vancouver, British Columbia, received written notice from Nasdaq that it is not in compliance with the continued listing requirement to maintain minimum market value of publicly held shares of $15 million. 

Arbutus Biopharma Corp., of Warminster, Pa., sold part of its royalty interest on future global net sales of Onpattro (patisiran, Alnylam Pharmaceuticals Inc.) to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada. 

Oncovita SAS, of Paris, said it entered a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform. Financial terms of the agreement were not disclosed.

Shares of San Diego-based Atyr Pharma Inc. (NASDAQ:LIFE) rose 6.3% to $5.45 on the company's first full day of trading following a 1-for-14 reverse split of its common stock that helped the company regain compliance with the Nasdaq minimum bid price requirement.